Holen Sie sich die Stockscreener-App
1.035
2.36%
-0.025
Schlusskurs vom Vortag:
$1.06
Offen:
$1.05
24-Stunden-Volumen:
15.33M
Relative Volume:
1.56
Marktkapitalisierung:
$310.59M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-0.69
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
-7.59%
1M Leistung:
-13.75%
6M Leistung:
-35.11%
1J Leistung:
-52.74%
1-Tages-Spanne:
$0.9501
$1.06
1-Wochen-Bereich:
$0.9501
$1.18
52-Wochen-Spanne:
$0.9501
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Vergleichen Sie PACB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.035 | 336.09M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Potential Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Not Without Risk - simplywall.st
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences - GuruFocus
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock N - GuruFocus
Where Pacific Biosciences Stands With Analysts - Benzinga
PACB Price Target Reduced by Piper Sandler Following Quarterly R - GuruFocus
Metagenomics Market Size, Share, Forecast & Trends Analysis Report 2025: Market to Soar to $6.71 Billion by 2031, Driven by Agri Genomics and Genome Mapping - GlobeNewswire Inc.
PacBio clears allegations after special investigation By Investing.com - Investing.com Canada
PACB Stock May Rise Following the Deal With Chulalongkorn University - Nasdaq
PacBio (PACB) Completes Probe into Employment Practices and Cybe - GuruFocus
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated - Yahoo Finance
Pacbio adjusts 2025 revenue guidance to $150M-$170M amid macroeconomic challenges - MSN
Pacific Biosciences of California First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings - GuruFocus
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates - Yahoo Finance
Pacific Biosciences of California Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript - Insider Monkey
Pacific Biosciences (PACB) Beats Revenue Expectations Amid ChallengesNews and Statistics - IndexBox
Pacific Biosciences of California Q1 2025 Earnings Call Transcript - MarketBeat
Pacific Biosciences: Q1 Earnings Snapshot - Norwalk Hour
PacBio Announces First Quarter 2025 Financial Results - GlobeNewswire
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Pacific Biosciences (PACB) Reports Q1 2025 Financials Amid Macroeconomic Challenges - GuruFocus
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1 - Yahoo Finance
PacBio Q1 2025 slides: Consumable growth offsets instrument revenue decline - Investing.com Canada
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
PacBio Reports Q1 2025 Financial Results, Announces Restructuring and Strategic Focus Shift - Nasdaq
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings | PACB Stock News - GuruFocus
Pacific Biosciences (PACB) Prepares for Q1 Earnings Announcement - GuruFocus
Earnings To Watch: Pacific Biosciences of California Inc (PACB) Reports Q1 2025 Result - GuruFocus
PacBio (PACB) Q1 Earnings: What To Expect - Yahoo Finance
Pacific Biosciences of California Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
PacBio (PACB) Launches Pioneering Genomic Project in Asia Pacific | PACB Stock News - GuruFocus
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
PacBio (PACB) Q4 Earnings Report Preview: What To Look For - Barchart.com
Pacific Biosciences of California (PACB) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Pacific Biosciences Says New Technology to Enhance HiFi Sequencing - marketscreener.com
PacBio Licenses CUHK AI Tech To Boost 5-Base Methylation Detection In HiFi Sequencing - Nasdaq
PacBio (PACB) Enhances Methylation Detection in HiFi Sequencing - GuruFocus
PacBio Licenses Advanced DNA Methylation Detection Technology to Enhance HiFi Sequencing Accuracy - Nasdaq
PACB stock touches 52-week low at $1.08 amid market challenges - Investing.com Australia
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know - Yahoo Finance
Pacific Biosciences of California Selected by Davos Alzheimer's Collaborative as Technology Partner - marketscreener.com
PacBio partners with global Alzheimer’s initiative By Investing.com - Investing.com India
PacBio partners with global Alzheimer’s initiative - Investing.com Australia
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.85%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):